International Stem Cell Corporation

OverviewSuggest Edit

International Stem Cell Corporation is a biotechnology company focused on therapeutic and research products. The Company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. International Stem Cell Corporation develops various cell types, including neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders, liver cells to treat various congenital and acquired liver diseases, and islet cells for the treatment of diabetes. It develops, manufactures, and markets skincare products and human cell culture products as well. 

TypePublic
Founded2001
HQCarlsbad, US
Websiteinternationalstemcell.com

Latest Updates

Employees (est.) (Dec 2018)48(+15%)
Revenue (FY, 2018)$11.1 M(+49%)

Key People/Management at International Stem Cell Corporation

Andrey Semechkin

Andrey Semechkin

Chief Executive Officer and Co-Chairman of the Board
Russell Kern

Russell Kern

Executive Vice President, Chief Scientific Officer
Francisco Bustamante

Francisco Bustamante

President of Lifeline Cell Technology, LLC
Sophia Garnette

Sophia Garnette

Vice President, Legal Affairs & Operations
Jeremy Hammond

Jeremy Hammond

Director of Quality Control
Glenn Sherman

Glenn Sherman

Director of Chemistry Manufacturing and Controls (CMC)
Show more

International Stem Cell Corporation Office Locations

International Stem Cell Corporation has offices in Carlsbad, Frederick and Oceanside
Carlsbad, US (HQ)
5950 Priestly Dr
Frederick, US
8415 Progress Drive Suite T
Oceanside, US
2595 Jason Ct
Show all (3)

International Stem Cell Corporation Financials and Metrics

International Stem Cell Corporation Revenue

Embed Graph
View revenue for all periods
International Stem Cell Corporation's revenue was reported to be $11.09 m in FY, 2018
USD

Revenue (Q2, 2019)

2.3m

Gross profit (Q2, 2019)

1.5m

Gross profit margin (Q2, 2019), %

63.1%

Net income (Q2, 2019)

(648.0k)

EBIT (Q2, 2019)

(941.0k)

Market capitalization (8-Oct-2018)

10.0m

Cash (30-Jun-2019)

595.0k
International Stem Cell Corporation's current market capitalization is $10 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

6.1m7.0m7.6b7.2m7.5m11.1m

Revenue growth, %

14%107510%(100%)4%

Cost of goods sold

1.6m1.9m2.1b1.9m2.1m4.1m

Gross profit

4.5m5.1m5.5b5.2m5.3m7.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

1.7m1.6m1.6m2.0m1.6m1.8b2.1b1.6b1.9b1.9b2.0b1.8m1.8b2.6m5.7m3.2m2.2m2.3m

Cost of goods sold

447.0k439.0k409.0k518.0k418.0k516.0m565.0m377.0m506.0m606.0m553.0m471.0k474.0m825.0k1.9m1.3m841.0k857.0k

Gross profit

1.2m1.2m1.2m1.4m1.2m1.3b1.6b1.2b1.4b1.3b1.5b1.3m1.4b1.8m3.8m1.9m1.4m1.5m

Gross profit Margin, %

73%73%74%74%74%72%74%77%74%69%72%73%74%69%66%59%62%63%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.2m1.1m532.0k110.0k304.0k1.1m

Accounts Receivable

306.0k574.0k465.0k

Prepaid Expenses

418.0k779.0k

Inventories

658.0k485.0k572.0k1.4m1.3m1.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

1.8m991.0k748.0k471.0k611.0k554.0k599.0k1.5m768.0k733.0k676.0k297.0k510.0k447.0k477.0k1.2m615.0k595.0k

Accounts Receivable

(110.0k)976.0k

Inventories

1.4m1.4m1.5m1.5m1.7m1.8m1.9m1.4m1.4m1.3m1.4m1.4m1.4m1.4m1.7m1.5m1.5m1.3m

Current Assets

4.0m3.5m3.2m2.9m3.1m3.3m3.6m4.1m3.3m3.1m3.3m2.8m3.1m3.4m4.3m4.7m3.5m3.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.5m)(12.5m)(2.6m)(1.1m)6.1m(2.1m)

Depreciation and Amortization

464.0k458.0k472.0k331.0k326.0k308.0k

Inventories

(260.0k)(215.0k)(217.0k)(157.0k)(129.0k)

Accounts Payable

(437.0k)138.0k422.0k(251.0k)(11.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(7.7m)(1.4m)(4.4m)(2.0m)(1.3m)723.0m(539.0m)(14.6b)10.9b414.0m(3.1b)(2.5m)(4.7m)(830.0k)(1.2m)(1.1m)(906.0k)(1.6m)

Depreciation and Amortization

347.0k116.0k165.0k248.0k68.0k140.0k215.0k72.0k138.0k

Inventories

(201.0k)8.0k(33.0k)(84.0k)51.0k184.0k

Accounts Payable

(447.0k)(14.0k)798.0k715.0k1.8m580.0k526.0k602.0k743.0k796.0k725.0k(450.0k)7.0k782.0k987.0k249.0k348.0k273.0k
USDY, 2019

Financial Leverage

-7.2 x
Show all financial metrics

International Stem Cell Corporation Revenue Breakdown

Embed Graph

International Stem Cell Corporation revenue breakdown by business segment: 30.3% from Cosmetic and 69.7% from Biomedical

International Stem Cell Corporation revenue breakdown by geographic segment: 85.1% from North America, 9.8% from Asia and 5.1% from Other

International Stem Cell Corporation Online and Social Media Presence

Embed Graph

International Stem Cell Corporation News and Updates

International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019

CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided …

International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results

CARLSBAD, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announ…

International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business

CARLSBAD, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based, clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced to…

Stem Cell Therapies Maket 2025: Analysis & Profit Gain Ideas with Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation

Global Stem Cell Therapies market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa. Posted via Industry Today. Follow us on Twitter @IndustryToday

International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018

CARLSBAD, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided…

International Stem Cell Corporation Granted Key US Patent Protecting Lead Therapeutic Program

CARLSBAD, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced tod…
Show more

International Stem Cell Corporation Blogs

Parthenogenesis: A Leading Trend in the Global Stem Cell Market

Stem cells are shown to be quite promising in the world of regenerative medicine, with the potential to treat a wide array of human diseases. However, stem cell therapy isn’t exactly uncharted territory. Surgeons have been performing bone marrow stem cell transplants for decades now. But, when scien…

International Stem Cell Corporation Frequently Asked Questions

  • When was International Stem Cell Corporation founded?

    International Stem Cell Corporation was founded in 2001.

  • Who are International Stem Cell Corporation key executives?

    International Stem Cell Corporation's key executives are Andrey Semechkin, Russell Kern and Francisco Bustamante.

  • How many employees does International Stem Cell Corporation have?

    International Stem Cell Corporation has 48 employees.

  • What is International Stem Cell Corporation revenue?

    Latest International Stem Cell Corporation annual revenue is $11.1 m.

  • What is International Stem Cell Corporation revenue per employee?

    Latest International Stem Cell Corporation revenue per employee is $231 k.

  • Who are International Stem Cell Corporation competitors?

    Competitors of International Stem Cell Corporation include ProtoKinetix, Cryo-Cell International and Clementia Pharmaceuticals.

  • Where is International Stem Cell Corporation headquarters?

    International Stem Cell Corporation headquarters is located at 5950 Priestly Dr, Carlsbad.

  • Where are International Stem Cell Corporation offices?

    International Stem Cell Corporation has offices in Carlsbad, Frederick and Oceanside.

  • How many offices does International Stem Cell Corporation have?

    International Stem Cell Corporation has 3 offices.